Lupin launches Risperidone extended-release injectable suspension in the U.S. with 180-day CGT…
The launch marks Lupin’s first product using PrecisionSphereTM, the long-acting injectable platform developed by Nanomi B.V.
Author
Zydus Lifesciences receives USFDA approval for Diroximel Fumarate delayed-release capsules
The approval covers the treatment of relapsing forms of multiple sclerosis in adults, with production to take place at Zydus…
Alembic receives USFDA approval for Dexlansoprazole delayed-release capsules
Alembic Pharmaceuticals secures final USFDA approval for Dexlansoprazole Delayed-Release Capsules, 30 mg and 60 mg,…
Lupin achieves S&P Global ESG Score of 91 for 2025, surpassing pharma industry average
Lupin reports a 91-point S&P Global ESG Score for 2025, exceeding the pharma industry average of 28 and marking a major rise…
Lupin receives EIR from U.S. FDA for Aurangabad facility
The Establishment Inspection Report follows a product-specific Pre-Approval Inspection conducted by the U.S. FDA at Lupin’s…
THSTI, Miltenyi Biotec and BIRAC launch India’s first hands-on training on cell and gene therapy…
The initiative focuses on building India’s capacity in CAR-T cell therapy through practical training and industry-academia…
Lupin manufacturing solutions commissions dedicated oncology block at Vizag facility
Lupin Manufacturing Solutions has commissioned a new high-containment oncology unit at its Vizag site to expand contract…
Novo Nordisk India reduces Wegovy prices by 37% to expand access for people
Novo Nordisk India has reduced the weekly price of the starting dose of Wegovy from INR 4,336 to INR 2,712, aiming to make…
Servier India launches biomarker testing initiative for AML and Cholangiocarcinoma patients
The programme is introduced in collaboration with MedGenome and Strand Life Sciences to expand access to molecular testing across…
Zydus receives NMPA approval in China for Venlafaxine extended-release capsules
This marks the first NMPA approval for Zydus in the Chinese market